The clinical application of the [99mTc]Tc-PSMA-I&S obtained from the evaluated PSMA-I&S cold kit was demonstrated in a 59-year-old PCa patient (ISUP grade = 3; PSA level = 25.7 ng/mL), exhibiting no evidence of metastatic disease during preoperative staging, which included bone scintigraphy and pelvic magnetic resonance imaging. This evidence concerns the gene FOLH1 and metastatic neoplasm.